• Access To Medicines

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

Randomized embedded multi-factorial platform trial to provide accelerated, real-world evidence in community acquired pneumonias including COVID-19, influenzas and bacterial pneumonias

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

• ETD001 is a novel inhaled, long-acting ENaC inhibitor • Therapy applicable to all cystic fibrosis patients, independent of genotype

How are companies across the Bruntwood SciTech network improving access to better healthcare, medicines and treatments?

The Bruntwood SciTech network is home to some of the UK’s most pioneering science companies, from small medtech startups and scaleups, all the way through to global life science companies that are uncovering world-leading discoveries, creating new medicines and shaping the future of our healthcare. So who are some of the UK’s most innovative life science businesses at the forefront of helping to create a fairer and healthier world?

ATTC network establishes first Advanced Therapies NHS Readiness Toolkit

The toolkit will enable widespread clinical adoption and improved patient access to advanced therapies across the UK

FairJourney Biologics enters next-generation antibody discovery collaboration with argenx

• Collaboration to leverage IONTAS proprietary mammalian display technology • Differentiated antibody candidates that emerge from collaboration may advance into argenx immunology pipeline

Guest Blog|Could our immune system be why COVID-19 is so deadly?

Respiratory viruses such as SARS-CoV-2 often catalyse an overactive immune response that leads to a life-threatening cycle, known as a cytokine storm. Analysing cytokine responses from patients has unearthed glaringly important differences in how SARS-CoV-2 affects cytokines compared to other common respiratory viruses.

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

• Potent antibodies shown to retain binding to major COVID-19-causing “South African” variant • IONTAS now seeking development partners

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies

Hikma and Arecor Expand Collaboration with New Agreement to Develop and Commercialise Ready-To-Administer Medicine

Hikma and Arecor today announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma’s affiliate, Hikma Pharmaceuticals USA Inc. The agreement builds on Hikma and Arecor’s first product co-development agreement, which was announced on 9 January 2020.

Advanced Therapy Treatment Centre network awarded £9.5m further investment

The UK Government grant will support new and existing projects until March 2022. Funding will ensure that the positive impact of the ATTC network continues; further optimising the UK ecosystem for routine adoption of advanced therapies.